{"id":31129,"date":"2025-02-25T16:31:15","date_gmt":"2025-02-25T11:01:15","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=31129"},"modified":"2025-02-26T15:52:16","modified_gmt":"2025-02-26T10:22:16","slug":"pharma-news-for-signet-bavarian-indivior","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior","title":{"rendered":"CTEXLI Approved for Cerebrotendinous Xanthomatosis; SIGX1094 Wins Fast Track for Diffuse Gastric Cancer; Bavarian Nordic\u2019s Chikungunya Vaccine Cleared for Ages 12+; UX111 Gene Therapy Gains Priority Review for Sanfilippo Syndrome; SUBLOCADE Label Update Approved"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f77ed386753\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f77ed386753\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior\/#FDA_Approves_CTEXLI_the_First-Ever_Treatment_for_Cerebrotendinous_Xanthomatosis_a_Rare_Lipid_Storage_Disorder\" >FDA Approves CTEXLI, the First-Ever Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disorder<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior\/#SIGX1094_Granted_FDA_Fast_Track_Designation_as_a_Potential_First_Targeted_Therapy_for_Diffuse_Gastric_Cancer\" >SIGX1094 Granted FDA Fast Track Designation as a Potential First Targeted Therapy for Diffuse Gastric Cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior\/#Bavarian_Nordics_Virus-Like_Particle_Chikungunya_Vaccine_Approved_by_FDA_for_Ages_12_and_Up\" >Bavarian Nordic\u2019s Virus-Like Particle Chikungunya Vaccine Approved by FDA for Ages 12 and Up<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior\/#Ultragenyx_Secures_FDA_Priority_Review_for_UX111_Gene_Therapy_to_Treat_Sanfilippo_Syndrome_Type_A\" >Ultragenyx Secures FDA Priority Review for UX111 Gene Therapy to Treat Sanfilippo Syndrome Type A<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior\/#Indivior_Receives_FDA_Approval_for_SUBLOCADE_Label_Updates\" >Indivior Receives FDA Approval for SUBLOCADE Label Updates<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-approves-ctexli-the-first-ever-treatment-for-cerebrotendinous-xanthomatosis-a-rare-lipid-storage-disorder\"><span class=\"ez-toc-section\" id=\"FDA_Approves_CTEXLI_the_First-Ever_Treatment_for_Cerebrotendinous_Xanthomatosis_a_Rare_Lipid_Storage_Disorder\"><\/span>FDA Approves CTEXLI, the First-Ever Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disorder<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Mirum Pharmaceuticals, Inc.<\/strong> announced that the<strong> FDA<\/strong> has approved <strong>CTEXLI (chenodiol) tablets<\/strong> as the <strong>first and only treatment<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/cerebrotendinous-xanthomatosis-market\"><strong>cerebrotendinous xanthomatosis (CTX)<\/strong><\/a>, a rare, progressive, and debilitating metabolic disease. CTX is caused by a deficiency of <strong>chenodeoxycholic acid (CDCA)<\/strong>, leading to the toxic accumulation of <strong>bile alcohols and cholestanol<\/strong>, which contribute to severe neurological and systemic complications.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA\u2019s approval of CTEXLI is tremendous as it unlocks an opportunity to better identify and treat adult patients with CTX in the United States,\u201d<\/em> said <strong>Chris Peetz<\/strong>, CEO of Mirum Pharmaceuticals. <em>\u201cOur hope is that patients are diagnosed sooner and can avoid some of the debilitating and lasting symptoms associated with CTX.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The approval is based on the <strong>Phase III RESTORE study<\/strong>, which demonstrated that CTEXLI significantly reduced <strong>urine bile alcohol levels (p&lt;0.0001)<\/strong> and improved <strong>serum cholestanol levels<\/strong>, key markers of disease progression. Patients on CTEXLI had <strong>a 20-fold lower<\/strong> bile alcohol level compared to those on placebo, and more placebo-treated patients required <strong>blinded rescue therapy<\/strong>, further highlighting the drug\u2019s effectiveness.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cCTX is a devastating disease that is often diagnosed in early adulthood with progressive symptoms that impact quality of life,\u201d<\/em> said <strong>Jean Pickford<\/strong>, Executive Director of the CTX Alliance. <em>\u201cWe are thrilled that CTEXLI is now approved and hope patients can receive treatment earlier to prevent irreversible complications.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sigx1094-granted-fda-fast-track-designation-as-a-potential-first-targeted-therapy-for-diffuse-gastric-cancer\"><span class=\"ez-toc-section\" id=\"SIGX1094_Granted_FDA_Fast_Track_Designation_as_a_Potential_First_Targeted_Therapy_for_Diffuse_Gastric_Cancer\"><\/span>SIGX1094 Granted FDA Fast Track Designation as a Potential First Targeted Therapy for Diffuse Gastric Cancer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Signet Therapeutics<\/strong>, a clinical-stage biotech company specializing in <strong>organoid- and AI-driven cancer drug discovery<\/strong>, announced that the <strong>FDA<\/strong> has granted <strong>Fast Track Designation<\/strong> to <strong>SIGX1094<\/strong>, the world\u2019s first potential <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastric-cancer-market\"><strong>targeted therapy for diffuse gastric cancer (DGC)<\/strong><\/a>. The designation aims to <strong>accelerate the development<\/strong> of therapies addressing serious diseases with <strong>unmet medical needs<\/strong>. In November 2024, <strong>SIGX1094<\/strong> also received an <strong>Orphan Drug Designation (ODD)<\/strong> from the FDA.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cReceiving Fast Track Designation for SIGX1094 underscores the FDA\u2019s recognition of both the serious, life-threatening nature of diffuse gastric cancer and the potential of SIGX1094 to address this critical medical need,\u201d<\/em> said <strong>Dr. Haisheng Zhang<\/strong>, founder and CEO of <strong>Signet Therapeutics<\/strong>. <em>\u201cThis milestone highlights our commitment to rapidly advancing innovative cancer treatments through our organoid and AI platform.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p><strong>SIGX1094<\/strong> was developed using Signet\u2019s <strong>proprietary organoid + AI drug discovery platform<\/strong>, in collaboration with <strong>XtalPi (2228.HK)<\/strong>, a leader in AI-driven drug discovery. It is the <strong>first therapy<\/strong> to be developed through the <strong>integration of organoid models and AI<\/strong>, marking a <strong>significant advancement<\/strong> in the treatment of <strong>DGC<\/strong>, a highly aggressive cancer with <strong>no approved targeted therapies<\/strong>. The drug is currently being <strong>evaluated in a Phase I clinical trial<\/strong> at <strong>Beijing Cancer Hospital<\/strong> in China.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cSIGX1094 represents a major step forward in the treatment of DGC, a cancer with very limited therapeutic options,\u201d<\/em> said <strong>Dr. Zhang<\/strong>. <em>\u201cFast Track Designation will allow us to work closely with the FDA to expedite its development and potentially bring this breakthrough therapy to patients sooner.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>With <strong>Fast Track Designation<\/strong>, Signet Therapeutics will benefit from <strong>early and frequent FDA interactions<\/strong>, potential <strong>accelerated approval<\/strong>, <strong>priority review<\/strong>, and <strong>rolling review<\/strong>\u2014all aimed at <strong>fast-tracking SIGX1094\u2019s path to market<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bavarian-nordic-s-virus-like-particle-chikungunya-vaccine-approved-by-fda-for-ages-12-and-up\"><span class=\"ez-toc-section\" id=\"Bavarian_Nordics_Virus-Like_Particle_Chikungunya_Vaccine_Approved_by_FDA_for_Ages_12_and_Up\"><\/span>Bavarian Nordic\u2019s Virus-Like Particle Chikungunya Vaccine Approved by FDA for Ages 12 and Up<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Bavarian Nordic A\/S <\/strong>announced that the <strong>FDA<\/strong> has approved <strong>VIMKUNYA (Chikungunya Vaccine, Recombinant)<\/strong> for individuals <strong>12 years and older<\/strong>, making it the <a href=\"https:\/\/www.delveinsight.com\/report-store\/chikungunya-market\"><strong>first virus-like particle (VLP) single-dose chikungunya vaccine<\/strong><\/a> in the U.S. The approval was granted under <strong>Priority Review<\/strong> based on results from <strong>two Phase III trials<\/strong> involving over <strong>3,500 participants<\/strong>, where up to <strong>97.8% of vaccinated individuals<\/strong> developed neutralizing antibodies within <strong>21 days<\/strong>. The vaccine was well tolerated, with <strong>mild to moderate adverse events<\/strong> reported.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe approval of our chikungunya vaccine is a testament to our unwavering commitment to addressing unmet medical needs and protecting communities worldwide,\u201d<\/em> said <strong>Paul Chaplin, President and CEO of Bavarian Nordic<\/strong>. <em>\u201cAs climate change expands the reach of mosquito-borne illnesses, this milestone underscores the importance of innovative solutions to safeguard travelers and vulnerable populations.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Alongside the approval, the <strong>FDA awarded Bavarian Nordic a Priority Review Voucher (PRV)<\/strong> under the <strong>Tropical Disease PRV program<\/strong>, which the company <strong>plans to monetize<\/strong> when the time is right. <strong>VIMKUNYA<\/strong> is set for <strong>commercial availability in the U.S. in the first half of 2025<\/strong>.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are proud to provide the first vaccine specifically approved for the prevention of chikungunya virus in individuals aged 12 and over, offering a critical tool to combat this growing health challenge,\u201d<\/em> added <strong>Chaplin<\/strong>.<\/p>\n<\/blockquote>\n\n\n\n<p>The vaccine also recently <strong>received a positive opinion from the EMA\u2019s Committee for Medicinal Products for Human Use (CHMP)<\/strong> and is expected to launch in <strong>key European markets in the first half of 2025<\/strong>, pending final approval by the <strong>European Commission<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ultragenyx-secures-fda-priority-review-for-ux111-gene-therapy-to-treat-sanfilippo-syndrome-type-a\"><span class=\"ez-toc-section\" id=\"Ultragenyx_Secures_FDA_Priority_Review_for_UX111_Gene_Therapy_to_Treat_Sanfilippo_Syndrome_Type_A\"><\/span>Ultragenyx Secures FDA Priority Review for UX111 Gene Therapy to Treat Sanfilippo Syndrome Type A<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Ultragenyx Pharmaceutical Inc. <\/strong>announced that the <strong>FDA <\/strong>has accepted its <strong>Biologics License Application (BLA) for UX111 (ABO-102),<\/strong> an AAV gene therapy for <a href=\"https:\/\/www.delveinsight.com\/report-store\/sanfilippo-syndrome-type-a-mps-iiia-market\"><strong>Sanfilippo syndrome type A (MPS IIIA)<\/strong><\/a><strong>.<\/strong> The FDA granted <strong>Priority Review<\/strong> with a <strong>PDUFA action date of August 18, 2025<\/strong>, signaling the potential for <strong>accelerated approval<\/strong> of the first-ever treatment for this devastating neurodegenerative disease. The FDA also indicated that it does <strong>not<\/strong> currently plan to hold an advisory committee meeting for the application.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAcceptance of the UX111 BLA brings us closer to providing a first-ever treatment for Sanfilippo syndrome type A, and if our application is successful, we\u2019re prepared to launch this therapy for patients and their families,\u201d<\/em> said <strong>Emil D. Kakkis, M.D., Ph.D., CEO and president of Ultragenyx<\/strong>. <em>\u201cBy reaching alignment with the Agency on a path forward for accelerated approval in neuronopathic MPS diseases, our UX111 program could help advance drug development for multiple metabolic diseases of the brain.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The BLA submission is backed by <strong>data from the pivotal Transpher A study and long-term follow-up trials<\/strong>, which demonstrated that UX111 led to a <strong>rapid and sustained decrease in cerebrospinal fluid (CSF) heparan sulfate (HS)<\/strong>, a key disease biomarker, regardless of patient age or disease stage. The treatment also showed <strong>statistically significant improvements<\/strong> in cognitive and communication functions compared to untreated patients. <strong>Mild to moderate liver enzyme elevations<\/strong> were the most common treatment-related adverse events, all resolved.<\/p>\n\n\n\n<p>If approved, <strong>UX111 would become the first gene therapy for Sanfilippo syndrome type A<\/strong>, offering new hope to families affected by this progressive and life-threatening disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-indivior-receives-fda-approval-for-sublocade-label-updates\"><span class=\"ez-toc-section\" id=\"Indivior_Receives_FDA_Approval_for_SUBLOCADE_Label_Updates\"><\/span>Indivior Receives FDA Approval for SUBLOCADE Label Updates<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Indivior PLC<\/strong> announced that the<strong> FDA<\/strong> has approved <strong>label updates<\/strong> for <strong>SUBLOCADE<\/strong>, introducing a <strong>rapid initiation protocol<\/strong> and <strong>alternative injection sites<\/strong>. These updates mark a significant step forward in <strong>improving treatment flexibility<\/strong> for <a href=\"https:\/\/www.delveinsight.com\/report-store\/opioid-use-disorder-market\"><strong>moderate to severe opioid use disorder (OUD)<\/strong><\/a>.<\/p>\n\n\n\n<p>Under the <strong>new rapid initiation protocol<\/strong>, healthcare providers can <strong>administer SUBLOCADE after a single dose of transmucosal buprenorphine<\/strong>, with just a one-hour observation period to confirm tolerability. Additionally, the FDA has <strong>expanded the approved injection sites<\/strong> beyond the abdomen to include the <strong>thigh, buttock, and back of the upper arm<\/strong>, increasing <strong>patient comfort and provider flexibility<\/strong> in delivering treatment.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThese label updates for SUBLOCADE underscore our dedication to evolving our treatment options to better serve individuals battling opioid use disorder,\u201d<\/em> said <strong>Dr. Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior<\/strong>. <em>\u201cThese enhancements not only reflect our commitment to patient-centered care but also our ongoing efforts to align our treatments with real-world clinical needs, thereby potentially improving patient adherence and outcomes.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The <strong>expanded flexibility<\/strong> in <strong>initiation and administration<\/strong> could help <strong>reduce treatment barriers, streamline care delivery, and improve patient retention rates<\/strong>. A clinical study supporting rapid induction, involving <strong>729 participants<\/strong>, demonstrated that <strong>66.4% of patients receiving the rapid initiation protocol continued treatment to the second injection<\/strong>, compared to <strong>54.5% in the standard induction group<\/strong>.<\/p>\n\n\n\n<p>With these updates, <strong>SUBLOCADE remains a proven, effective option for opioid use disorder treatment<\/strong>, while adapting to patient needs and healthcare environments.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Approves CTEXLI, the First-Ever Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disorder Mirum Pharmaceuticals, Inc. announced that the FDA has approved CTEXLI (chenodiol) tablets as the first and only treatment for cerebrotendinous xanthomatosis (CTX), a rare, progressive, and debilitating metabolic disease. CTX is caused by a deficiency of chenodeoxycholic acid (CDCA), leading to [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31130,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[21167,21511,21512,204,704,16958,349,420,20678,639,5789,6763],"industry":[17225],"therapeutic_areas":[17238,17231,17228,18276],"class_list":["post-31129","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-chikungunya","tag-chikungunya-treatment","tag-chikungunya-vaccine","tag-delveinsight","tag-fda","tag-gastric-cancer","tag-latest-pharma-news","tag-news","tag-opioid-use-disorder","tag-pharma-news","tag-recent-pharma-news","tag-sanfilippo-syndrome","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-oncology","therapeutic_areas-toxicology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Signet, Bavarian, Indivior<\/title>\n<meta name=\"description\" content=\"Mirum Pharmaceuticals\u2019 CTEXLI, Signet Therapeutics\u2019 SIGX1094, Bavarian Nordic\u2019s VIMKUNYA, Ultragenyx\u2019s UX111, Indivior\u2019s SUBLOCADE\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Signet, Bavarian, Indivior\" \/>\n<meta property=\"og:description\" content=\"Mirum Pharmaceuticals\u2019 CTEXLI, Signet Therapeutics\u2019 SIGX1094, Bavarian Nordic\u2019s VIMKUNYA, Ultragenyx\u2019s UX111, Indivior\u2019s SUBLOCADE\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-25T11:01:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-26T10:22:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/25162958\/pharma-news-for-signet-bavarian-indivior.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Signet, Bavarian, Indivior","description":"Mirum Pharmaceuticals\u2019 CTEXLI, Signet Therapeutics\u2019 SIGX1094, Bavarian Nordic\u2019s VIMKUNYA, Ultragenyx\u2019s UX111, Indivior\u2019s SUBLOCADE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Signet, Bavarian, Indivior","og_description":"Mirum Pharmaceuticals\u2019 CTEXLI, Signet Therapeutics\u2019 SIGX1094, Bavarian Nordic\u2019s VIMKUNYA, Ultragenyx\u2019s UX111, Indivior\u2019s SUBLOCADE","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-25T11:01:15+00:00","article_modified_time":"2025-02-26T10:22:16+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/25162958\/pharma-news-for-signet-bavarian-indivior.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior","name":"Pharma News | Signet, Bavarian, Indivior","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/25162958\/pharma-news-for-signet-bavarian-indivior.png","datePublished":"2025-02-25T11:01:15+00:00","dateModified":"2025-02-26T10:22:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Mirum Pharmaceuticals\u2019 CTEXLI, Signet Therapeutics\u2019 SIGX1094, Bavarian Nordic\u2019s VIMKUNYA, Ultragenyx\u2019s UX111, Indivior\u2019s SUBLOCADE","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-signet-bavarian-indivior#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/25162958\/pharma-news-for-signet-bavarian-indivior.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/25162958\/pharma-news-for-signet-bavarian-indivior.png","width":772,"height":482,"caption":"pharma-news-for-signet-bavarian-indivior"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/25162958\/pharma-news-for-signet-bavarian-indivior-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chikungunya<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chikungunya Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chikungunya Vaccine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gastric cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Opioid Use Disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanfilippo syndrome<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Chikungunya<\/span>","<span class=\"advgb-post-tax-term\">Chikungunya Treatment<\/span>","<span class=\"advgb-post-tax-term\">Chikungunya Vaccine<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gastric cancer<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Opioid Use Disorder<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Sanfilippo syndrome<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 25, 2025","modified":"Updated on Feb 26, 2025"},"absolute_dates_time":{"created":"Posted on Feb 25, 2025 4:31 pm","modified":"Updated on Feb 26, 2025 3:52 pm"},"featured_img_caption":"pharma-news-for-signet-bavarian-indivior\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=31129"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31129\/revisions"}],"predecessor-version":[{"id":31154,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/31129\/revisions\/31154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31130"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=31129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=31129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=31129"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=31129"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=31129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}